All In Biotech

Drug Trial Radar · NCT02047981

Mortality Reduction After Oral Azithromycin: Mortality Study

Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Mortality Trial

Last checked: Nov 19, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 190,238 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190,238

Actual

Start

Dec 2014

Primary completion

Sep 2018

Study completion Sep 2018

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation; Johns Hopkins University; London School of Hygiene and Tropical Medicine
First posted
Jan 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 1 month, up to 60 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.

Conditions

  • Childhood Mortality

Interventions

  • AzithromycinDrug

    Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.

  • PlaceboDrug

    Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause Mortality Rate in Children Aged 1-60 MonthsTime frame: 24 Months
  2. All-cause Mortality Rate in Children Aged 1-60 MonthsTime frame: 36 months

Locations

6 sites in 5 countries. Site status is shown where the registry gives one.

  • UCSF Proctor Foundation

    San Francisco, California

  • Johns Hopkins University

    Baltimore, Maryland

  • College of Medicine at the University of Malawi, Blantyre

    Blantyre, Malawi

  • The Carter Center, Niger

    Niamey, Niger

  • Kongwa Trachoma Project

    Kongwa, Tanzania

  • London School of Hygiene & Tropical Medicine

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.